≡ Risteys R6

Methods Changelog GitHub Contact & Feedback

Sodium-glucose co-transporter 2 (SGLT2) inhibitors

PheWeb

No definition available.

Endpoint definition

↥
FinnGen phenotype data
diagram bullet diagram downward connector

Filter registries KELA purch., KELA reimb.

Medicine purchases: ATC A10BJ
Medicine purchases: ATC: other data required >3 instances required

Check pre-conditions None

Include endpoints None

Check conditions None

Apply sex-specific rule None

diagram downward connector SGLT2INH

Extra metadata

First used in FinnGen datafreeze DF2

Summary Statistics

↥

Key figures

All Female Male
Number of individuals 2537 1271 1266
Unadjusted prevalence (%) 0.98 0.86 1.12
Mean age at first event (years) 61.60 60.69 62.51

Mortality

Follow-up Absolute risk HR [95% CI] p N
1998–2019 0.09 6.77 [4.19, 10.94] 5.4e-15 36
15 years 0.04 6.77 [4.19, 10.94] 5.4e-15 36
5 years 0.01 6.77 [4.19, 10.94] 5.4e-15 36
1 year - - - -

Correlations

↥

Index endpoint: SGLT2INH – Sodium-glucose co-transporter 2 (SGLT2) inhibitors
GWS hits:

Survival analyses between endpoints

↥

Plot

before Sodium-glucose co-transporter 2 (SGLT2) inhibitors
after Sodium-glucose co-transporter 2 (SGLT2) inhibitors

loading spinner Loading survival analyses plot

Drugs most likely to be purchased after Sodium-glucose co-transporter 2 (SGLT2) inhibitors

↥